To explore the therapy strategies for R/R MCL, especially those with multiple defects on key genes such as ATM and TP53, we screened numerous promising compounds targeting DDR, p53 signaling, and cell cycle, including PRMT5 inhibitors, for their cytotoxicity on MCL cell lines with different genetic backgrounds. This evidence concerns the gene TP53 and mantle cell lymphoma.